Steven Cohen’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$53.9M Buy
3,697,803
+2,913,617
+372% +$51.7M 0.06% 406
2026
Q1
$14.9M Buy
+784,186
New +$12.7M 0.02% 986
2019
Q1
Sell
-445,991
Closed -$513K 1216
2018
Q4
$513K Sell
445,991
-18,639
-4% -$29K ﹤0.01% 872
2018
Q3
$1.03M Sell
464,630
-262,090
-36% -$604K ﹤0.01% 845
2018
Q2
$1.78M Sell
726,720
-23,280
-3% -$298K 0.01% 765
2018
Q1
$9.68M Sell
750,000
-35,600
-5% -$445K 0.04% 435
2017
Q4
$8.7M Sell
785,600
-20,871
-3% -$233K 0.04% 475
2017
Q3
$10.1M Buy
806,471
+5,240
+0.7% +$67.9K 0.05% 393
2017
Q2
$9.13M Hold
801,231
0.05% 407
2017
Q1
$10.6M Sell
801,231
-124,968
-13% -$1.45M 0.06% 391
2016
Q4
$7.93M Hold
926,199
0.06% 361
2016
Q3
$8.39M Hold
926,199
0.06% 312
2016
Q2
$7.49M Sell
926,199
-3,800
-0.4% -$30.9K 0.05% 350
2016
Q1
$6.34M Sell
929,999
-1
-0% -$8 0.05% 387
2015
Q4
$10.7M Buy
930,000
+10,361
+1% +$108K 0.09% 273
2015
Q3
$9.57M Buy
919,639
+7,736
+0.8% +$92.7K 0.08% 309
2015
Q2
$9.63M Buy
911,903
+68,603
+8% +$777K 0.07% 331
2015
Q1
$10.4M Buy
+843,300
New +$9.55M 0.07% 322

Other funds holding SMMT

Steven Cohen's SMMT Position: Q2 2026 in Review

Steven Cohen increased its Summit Therapeutics (SMMT) stake by 372% in Q2 2026, buying an estimated $51.7M and bringing the position to 3,697,803 shares worth $53.9M. The position accounts for 0.06% of the portfolio, ranked #406.

Steven Cohen first reported a position in SMMT in Q1 2015 and has held it in 18 quarters since. 241 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Steven Cohen held 3,697,803 shares of Summit Therapeutics worth $53.9M as of Q2 2026.
  • Steven Cohen bought 2,913,617 Summit Therapeutics shares in Q2 2026, an estimated $51.7M.
  • Summit Therapeutics made up 0.06% of Steven Cohen's portfolio in Q2 2026, its #406 holding.
  • Steven Cohen first reported a position in Summit Therapeutics in Q1 2015 and has held it in 18 quarters since.
  • 241 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.